Breaking News

The Groninger Group Acquires Reinraumtechnik Ulm (RTU)

Expands its technological portfolio and strengthens its expertise in cleanroom and isolator technology.

Left to right: Jens Groninger, CEO of the groninger Group, and Dietmar Renz, founder of RTU.

The groninger Group has acquired Reinraumtechnik Ulm GmbH (RTU), thereby expanding its technological portfolio and strengthening its expertise in cleanroom and isolator technology.

“With Reinraumtechnik Ulm, we’re gaining more than just technological expertise – we’re welcoming a fantastic team that’s passionate about innovation, precision, and quality,” said Jens Groninger, CEO of the groninger Group. “From now on, we’ll be shaping the future of the pharmaceutical industry together – boldly, with vision, and hand in hand under the groninger Group umbrella.”

Reinraumtechnik Ulm is a specialist in the pharma and biotech sectors, known for its customized cleanroom systems and isolator technology. Based in Ulm, the company has been developing tailored solutions for demanding pharmaceutical applications for over two decades.

“Our customers have increasingly expressed the desire for an expanded product portfolio – with the acquisition of RTU, we’re responding decisively to that demand,” added Groninger. “The long-term goal is to support customers worldwide with holistic solutions – reliably, collaboratively, and driven by innovation.”

As part of the acquisition, RTU founder Dietmar Renz will gradually step away from day-to-day operations. Steffen Rieger will continue to serve as Managing Director of RTU even after the integration into the groninger Group. With his deep understanding and expertise in the product portfolio, he will ensure stability and reliability in daily operations. Reinraumtechnik Ulm will remain an independent company with its own expertise and location in Ulm – embedded within the groninger Group, but maintaining its identity.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics